NCT00000792View on ClinicalTrials.gov

A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

Not specified

Study Completion Date

January 31, 1995

Conditions

HIV Infections

Interventions

DRUG

Hypericin

Trial Locations (3)

10016

NY Univ. HIV/AIDS CRS, New York

21287

Johns Hopkins Adult AIDS CRS, Baltimore

02215

Beth Israel Deaconess - East Campus A0102 CRS, Boston

Sponsors

Collaborators (1)

VIMRx Pharmaceuticals

All Listed Sponsors

collaborator

VIMRx Pharmaceuticals

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000792 - A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects | Biotech Hunter | Biotech Hunter